AzTrials
AzTrials

Preterm BirthNCT07844499

Labor Characteristics and Maternal-Infant Outcomes in Preterm Primiparous Women

An observational study of Preterm Birth, run by Maternal and Child Health Hospital, Jiading District at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This retrospective observational study evaluates labor characteristics in primiparous women with spontaneous preterm birth at different gestational ages and examines their associations with maternal and neonatal outcomes. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Preterm Birth
What is being tested?
Gestational Age at Delivery
How many people
436 participants
Where
1 siteChina
Study dates
1 Jan 2020to 31 Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Primiparous women with spontaneous preterm birth who delivered vaginally at Shanghai Jiading District Maternity and Child Health Care Hospital between January 1, 2020, and December 31, 2025, were identified retrospectively from the hospital electronic medical record system. Eligible women had a singleton pregnancy with vertex presentation and delivered between 28 weeks 0 days and 36 weeks 6 days of gestation. Participants were classified according to gestational age at delivery into very preterm, moderate preterm, and late preterm groups.

Who may be able to join

  • Primiparous women undergoing vaginal delivery.
  • Gestational age at delivery from 28 weeks 0 days to 36 weeks 6 days.
  • Spontaneous preterm labor.
  • Singleton pregnancy with vertex presentation.
  • No labor interventions such as administration of uterotonic agents for labor augmentation or artificial rupture of membranes during labor.
  • Complete clinical records.

Who cannot join

  • Labor induction due to intrauterine fetal demise.
  • Twin or multiple pregnancy.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Maternal and Child Health Hospital, Jiading District

    Shanghai, Shanghai Municipality, 201821

Other trials in China

About this study

Official title: Labor Characteristics of Primiparous Women With Spontaneous Preterm Birth at Different Gestational Ages and Their Association With Maternal and Infant Outcomes

This retrospective observational study evaluates labor characteristics in primiparous women with spontaneous preterm birth at different gestational ages and examines their associations with maternal and neonatal outcomes. Medical records of women who delivered at Shanghai Jiading District Maternity and Child Health Care Hospital between January 1, 2020, and December 31, 2025, are reviewed.

Participants are classified according to gestational age at delivery into very preterm (28 to 31+6 weeks), moderate preterm (32 to 33+6 weeks), and late preterm (34 to 36+6 weeks) groups. The study compares the onset and duration of the active phase of labor, cervical dilation rate, and durations of the first and second stages of labor across these gestational-age groups.

The study also evaluates the associations between labor duration and maternal and neonatal outcomes, including postpartum blood loss, mode of vaginal delivery, and 5-minute Apgar score. The findings are intended to provide evidence for gestational age-specific and individualized labor management in women with spontaneous preterm birth.

Read the detailed description

This is a single-center, retrospective observational study based on electronic medical records from Shanghai Jiading District Maternity and Child Health Care Hospital. The study population consists of primiparous women with spontaneous preterm birth at 28 to 36+6 weeks of gestation who delivered vaginally between January 1, 2020, and December 31, 2025.

Participants are categorized into three gestational-age groups: very preterm (28 to 31+6 weeks), moderate preterm (32 to 33+6 weeks), and late preterm (34 to 36+6 weeks). Labor characteristics assessed include cervical dilation at the onset of the active phase, duration of the active phase, mean cervical dilation rate during the active phase, duration of the first stage of labor, and duration of the second stage of labor. The study also evaluates differences in labor duration according to the use of epidural labor analgesia.

Maternal and neonatal variables collected from the medical records include maternal age, gravidity, pre-pregnancy body mass index, gestational age at delivery, pregnancy-related complications and comorbidities, neonatal birth weight, vaginal delivery status, postpartum blood loss within 2 hours after delivery, postpartum hemoglobin level, and 5-minute Apgar score.

Associations between the durations of the first and second stages of labor and maternal or neonatal outcomes are evaluated using regression analyses with adjustment for relevant potential confounding variables. Linear regression is used to assess postpartum blood loss, multinomial logistic regression is used to evaluate vaginal delivery outcomes, and binary logistic regression is used to evaluate neonatal Apgar outcomes. Restricted cubic spline analyses are used to explore potential dose-response relationships between labor duration and outcomes showing statistically significant associations.

The study is non-interventional. All information is obtained retrospectively from existing medical records and is analyzed after de-identification.

Conditions
Preterm Birth
Being tested
Gestational Age at Delivery
Keywords
Spontaneous Preterm Birth, Primiparous Women, Gestational Age, Labor Duration, Active Phase of Labor, Cervical Dilation, First Stage of Labor, Second Stage of Labor, Maternal Outcomes, Neonatal Outcomes, Epidural Analgesia, Postpartum Blood Loss, Apgar Score
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gestational Age at DeliveryOther

    Gestational age at delivery was the primary exposure of interest. Participants were retrospectively classified into three groups according to gestational age at delivery: very preterm (28 weeks 0 days to 31 weeks 6 days), moderate preterm (32 weeks 0 days to 33 weeks 6 days), and late preterm (34 weeks 0 days to 36 weeks 6 days). No study-specific intervention was assigned, and all exposure and outcome information was obtained from existing medical records.

Study groups in NCT07844499
Study groupRoleWhat they receive
Very Preterm GroupPrimiparous women with spontaneous preterm birth who delivered vaginally at 28 weeks 0 days to 31 weeks 6 days of gestation. This group included 45 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Receives: Other: Gestational Age at Delivery
Moderate Preterm GroupPrimiparous women with spontaneous preterm birth who delivered vaginally at 32 weeks 0 days to 33 weeks 6 days of gestation. This group included 37 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Receives: Other: Gestational Age at Delivery
Late Preterm GroupPrimiparous women with spontaneous preterm birth who delivered vaginally at 34 weeks 0 days to 36 weeks 6 days of gestation. This group included 354 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Receives: Other: Gestational Age at Delivery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of the Active Phase of Labor

    Duration of the active phase of labor, measured in hours, from the onset of the active phase to full cervical dilation (10 cm). The onset of the active phase was defined as the cervical dilation corresponding to the inflection point at which the cervical dilation curve changed from a gradual slope to its maximum slope.

    Measured: During labor, from the identified onset of the active phase to full cervical dilation (10 cm)

  2. Title Description Time Frame Cervical Dilation at the Onset of the Active Phase

    Cervical dilation, measured in centimeters, at the identified onset of the active phase of labor.

    Measured: At onset of the active phase during the index delivery

  3. Mean Cervical Dilation Rate During the Active Phase

    Mean cervical dilation rate, measured in cm/hour, calculated as (10 cm minus cervical dilation at the onset of the active phase) divided by the duration of the active phase.

    Measured: During labor, from the identified onset of the active phase to full cervical dilation (10 cm)

  4. Duration of the First Stage of Labor

    Duration of the first stage of labor, measured in hours, as documented in the obstetric medical record.

    Measured: During labor, from the documented onset of labor to full cervical dilation (10 cm)

  5. Duration of the Second Stage of Labor

    Duration of the second stage of labor, measured in hours, from full cervical dilation to delivery of the fetus.

    Measured: During labor, from full cervical dilation (10 cm) to fetal delivery

Secondary outcomes (3)
  1. Postpartum Blood Loss Within 2 Hours After Delivery

    Postpartum blood loss within 2 hours after delivery, measured in milliliters using the gravimetric weighing method and documented in the medical record.

    Measured: From fetal delivery through 2 hours postpartum

  2. Vaginal Delivery Status

    Vaginal delivery status categorized as spontaneous vaginal delivery, episiotomy, or forceps-assisted vaginal delivery, as documented in the medical record.

    Measured: At the time of delivery

  3. 5-Minute Apgar Score

    Neonatal Apgar score assessed 5 minutes after birth and documented in the medical record. The score was evaluated to assess neonatal condition after delivery.

    Measured: 5 minutes after birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2026
  2. Study start1 Jan 2020
  3. Primary completion31 Dec 2025
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
436 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07844499
Sponsor's protocol ID
JDMCH-2026-036
Status last verified
Sep 2026
First submitted
18 Sep 2026
Last updated
28 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data underlying the reported study results may be shared with qualified researchers upon reasonable request to the corresponding author. The shared data may include relevant maternal characteristics, gestational age at delivery, labor characteristics, maternal outcomes, and neonatal outcomes. No directly identifiable participant information will be provided. Data sharing will be subject to institutional approval and applicable privacy and data protection requirements.

Questions about this trial

What is this clinical trial studying?

An observational study of Preterm Birth, run by Maternal and Child Health Hospital, Jiading District at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of the Active Phase of Labor (time frame: During labor, from the identified onset of the active phase to full cervical dilation (10 cm)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in